- Bupa Platinum consultant
- Fee assured
- Awaiting verification
- Open Referral network
- Video and telephone consultations
- Home chemotherapy
Dr Jonathan Lambert BMBS BMedSci PhD FRCP FRCPath is a Consultant Haemato-oncologist at University College Hospital London and Mount Vernon Cancer Centre. He undertook his specialist training in haematology in London, based at University College Hospital and completed a PhD in molecular haematology at the UCL Cancer Institute, resulting in a number of published papers in leading peer-reviewed journals.
He has specialist expertise in managing patients with lymphoma and myeloproliferative disorders (including essential thrombocythaemia, polycythaemia vera and myelofibrosis).
At University College Hospital, London, Dr Lambert is involved in running the lymphoma and myeloproliferative services and is clinical lead for lymphoma at Mount Vernon Cancer Centre. At both sites he has a particular interest in treating patients with the most complex or challenging cases.
Dr Lambert is involved in developing research in haematological cancers at both a local and a national level, and serves on a number of national research and clinical guideline committees. He is also responsible for the undergraduate teaching of haematology at UCL Medical School.
Areas of interest
Lymphoma; Hodgkin lymphoma; Non-Hodgkin lymphoma;
Myeloproliferative neoplasms; Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera; Systemic mastocytosis
Current NHS consultant posts held
Consultant Haemato-oncologist at University College Hospital London and Mount Vernon Cancer Centre.
Reference number 4645665
- University College Hospital235 Euston...
- 15:00 - 16:30
- 020 3447 1719
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)